{"id":389758,"date":"2022-11-15T00:00:00","date_gmt":"2022-11-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2022-biopharma-colorectal-cancer-disease-landscape-forecast-g7-2022\/"},"modified":"2026-05-12T11:28:33","modified_gmt":"2026-05-12T11:28:33","slug":"dlsfon0002-2022-biopharma-colorectal-cancer-disease-landscape-forecast-g7-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2022-biopharma-colorectal-cancer-disease-landscape-forecast-g7-2022\/","title":{"rendered":"Colorectal Cancer | Disease Landscape &#038; Forecast | G7 | 2022"},"content":{"rendered":"<p>Chemotherapy remains the cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. The colorectal cancer treatment landscape has shifted toward personalized treatment, with tumor sidedness and various biomarkers playing an important role in treatment selection. The colorectal cancer market is changing, largely fueled by the entry of immune checkpoint inhibitors (Merck &#038; Co.\u2019s Keytruda and Bristol Myers Squibb\u2019s Opdivo) and BRAF inhibitors (Array BioPharma \/ Pfizer\u2019s Braftovi). Both Opdivo (with or without Yervoy) and Keytruda are approved for advanced or recurrent MSI-H \/ dMMR colorectal cancer. Keytruda is also approved as first-line treatment for MSI-H \/ dMMR metastatic colorectal cancer. Braftovi in combination with an EGFR inhibitor (Erbitux) is now available for use as subsequent therapy for metastatic colorectal cancer patients with a <em>BRAF V600E<\/em> mutation. Given the intense Phase II\/III pipeline activity, we anticipate the approval of several new therapies for colorectal cancer during the forecast period, such as the VEGFR inhibitor fruquintinib (Hutchmed) and KRAS inhibitor adagrasib (Mirati Therapeutics). These therapies will contribute to the robust market growth anticipated over the 2021-2031 forecast period.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers, and how will drug-treatment rates change over the 2021-2031 forecast period?<\/li>\n<li>What are interviewed experts\u2019 views on current and emerging late-phase therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?<\/li>\n<li>Which are the most promising emerging therapies in the late-phase pipeline that are poised to launch for colorectal cancer, and what unmet needs do they address? What uptake and patient shares can late-phase pipeline agents currently in development for colorectal cancer expect to secure?<\/li>\n<li>What are the key drivers and constraints in the colorectal cancer market, and how will they change in the major markets over the forecast period?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p>SOLUTION ENHANCEMENT<\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-389758","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389758\/revisions"}],"predecessor-version":[{"id":576188,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389758\/revisions\/576188"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}